"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.
Ryan Haumschild, PharmD, MS, MBA, CPEL
Advertisement
Articles by Ryan Haumschild, PharmD, MS, MBA, CPEL
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
Community practice experience shows early efficacy, favorable safety with nadofaragene
2
Sean P. Collins, MD, PhD, outlines the impact of rectal spacers for men with prostate cancer
3
ORIC-944 shows promise in combination with ARPIs for mCRPC
4
Suzanne Merrill, MD, on integrating ICIs into clinical practice for NMIBC
5
